Understand entirely your skepticism, its healthy and realistic, but with the NIH and CTSN involved, this is no longer a virtually unknown company. Cardiothoracic surgeons across America's cardiohoracic trials network know about this company. They are faced with a lung deisease they cannot combat. They will be waited for this with bated breath. When the results come out there is no way this thing does not erupt in the news if it is efficacious.
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-347
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.000(0.00%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $1.959M | 1.673M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 251 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 44723 | 10 |
View Market Depth
| Last trade - 12.16pm 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |